Views

CrossRef citations to date

Altmetric

Colorectal cancer

The relationship between rash, tumour KRAS mutation status and clinical and quality of life outcomes in patients with advanced colorectal cancer treated with cetuximab in the NCIC CTG/AGITG CO.17

Dirkje W. SommeijerNational Health and Medical Research Council Clinical Trials Centre, University of Sydney, Sydney, New South Wales, AustraliaCorrespondence[email protected]

Christos S. KarapetisFlinders Medical Centre and Flinders University, Adelaide, South Australia, Australia

John R. ZalcbergDivision of Medicine, Peter MacCallum Cancer Centre and Departments of Medicine and Oncology, University of Melbourne, Melbourne, Victoria, Australia

Dongsheng TuNCIC Clinical Trials Group, Queen’s University, Kingston, Ontario, Canada

Derek J. JonkerThe Ottawa Hospital Research Institute, University of Ottawa, Ottawa, Ontario, Canada

John SimesNational Health and Medical Research Council Clinical Trials Centre, University of Sydney, Sydney, New South Wales, Australia

Niall TebbuttAustin Health, University of Melbourne, Heidelberg, Victoria, Australia

Desmond YipThe Canberra Hospital, Garran, ACT, Australia

Timothy J. PriceThe Queen Elizabeth Hospital and University of Adelaide, Woodville, South Australia, Australia

Chris J. O’CallaghanNCIC Clinical Trials Group, Queen’s University, Kingston, Ontario, Canada

show all

Citations (7)

Keep up to date with the latest research on this topic with citation updates for this article.

Articles from other publishers (7)

Kengo Hirayama, Ya Su, Megumi Chiba, Miku Izutsu & Michiko Yuki. (2020) Relationships between quality of life and skin toxicities of epidermal growth factor receptor inhibitors in cancer patients: A literature review. Japan Journal of Nursing Science 17:3.
Crossref

Sai-xi Bai, Ruo-rong Zhang, Wang-hua Chen, Hong-min Dong, Gang Wang, Xiao-kai Li & Wenling Wang. (2020) Clinical efficacy and safety of nimotuzumab plus chemotherapy in patients with advanced colorectal cancer: a retrospective analysis. Journal of International Medical Research 48:1, pages 030006051989585.
Crossref

Shigeyoshi Iwamoto, Akira Ooki, Satoshi Morita, Hiroki Hara, Hiroaki Tanioka, Hironaga Satake, Masato Kataoka, Masahito Kotaka, Yoshinori Kagawa, Masato Nakamura, Tatsushi Shingai, Masashi Ishikawa, Yasuhiro Miyake, Takeshi Sudo, Yojiro Hashiguchi, Taichi Yabuno, Junichi Sakamoto, Akihito Tsuji, Masahiko Ando & Kensei Yamaguchi. (2018) A prospective Phase II study to examine the relationship between quality of life and adverse events of first‐line chemotherapy plus cetuximab in patients with KRAS wild‐type unresectable metastatic colorectal cancer: QUACK trial. Cancer Medicine 7:9, pages 4217-4227.
Crossref

Mario E. Lacouture, Milan Anadkat, Aminah Jatoi, Tamer Garawin, Chet Bohac & Edith Mitchell. (2018) Dermatologic Toxicity Occurring During Anti-EGFR Monoclonal Inhibitor Therapy in Patients With Metastatic Colorectal Cancer: A Systematic Review. Clinical Colorectal Cancer 17:2, pages 85-96.
Crossref

Jing Hu, Zhen Zhang, Rui Zheng, Lei Cheng, Mi Yang, Li Li, Baorui Liu & Xiaoping Qian. (2016) On-treatment markers as predictors to guide anti-EGFR MoAb treatment in metastatic colorectal cancer: a systematic review with meta-analysis. Cancer Chemotherapy and Pharmacology 79:2, pages 275-285.
Crossref

Dalyong Kim, Yong Sang Hong, Jeong Eun Kim, Kyu-pyo Kim, Jae-Lyun Lee, Sung-Min Chun, Jihun Kim, Se Jin Jang & Tae Won Kim. (2017) Use of a High-Throughput Genotyping Platform (OncoMap) for <i>RAS</i> Mutational Analysis to Predict Cetuximab Efficacy in Patients with Metastatic Colorectal Cancer. Cancer Research and Treatment 49:1, pages 37-43.
Crossref

Veena Shankaran. (2015) Cost Considerations in the Evaluation and Treatment of Colorectal Cancer. Current Treatment Options in Oncology 16:8.
Crossref

Reprints and Corporate Permissions

Please note: Selecting permissions does not provide access to the full text of the article, please see our help page How do I view content?

To request a reprint or corporate permissions for this article, please click on the relevant link below:

Order Reprints Request Corporate Permissions

Academic Permissions

Please note: Selecting permissions does not provide access to the full text of the article, please see our help page How do I view content?

Obtain permissions instantly via Rightslink by clicking on the button below:

Request Academic Permissions

If you are unable to obtain permissions via Rightslink, please complete and submit this Permissions form. For more information, please visit our Permissions help page.

The relationship between rash, tumour KRAS mutation status and clinical and quality of life outcomes in patients with advanced colorectal cancer treated with cetuximab in the NCIC CTG/AGITG CO.17

Articles from other publishers (7)

Information for

Open access

Opportunities

Help and information

Your download is now in progress and you may close this window

Login or register to access this feature

The relationship between rash, tumour KRAS mutation status and clinical and quality of life outcomes in patients with advanced colorectal cancer treated with cetuximab in the NCIC CTG/AGITG CO.17

Citations (7)

Articles from other publishers (7)

Reprints and Corporate Permissions

Academic Permissions

Related research

To cite this article:

Download citation

Information for

Open access

Opportunities

Help and information

Keep up to date